FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2989133719> ?p ?o ?g. }

• W2989133719 endingPage "219" @default.
• W2989133719 startingPage "219" @default.
• W2989133719 abstract "This study reports the integrated analysis of two phase III studies of novel β-lactam/β-lactamase combination versus meropenem for treating nosocomial pneumonia (NP) including ventilator-associated pneumonia (VAP). The ASPECT-NP trial compared the efficacy and safety of ceftolozane–tazobactam versus meropenem for treating NP/VAP. The REPROVE trial compared ceftazidime–avibactam and meropenem in the treatment of NP/VAP. A total of 1528 patients (361 in the ceftolozane–tazobactam group; 405 in the ceftazidime–avibactam group; 762 in the meropenem group) were analyzed. The clinical cure rates at test-of-cure among the novel β-lactam/β-lactamase combinations group were non-inferior to those of the meropenem (70.7% vs. 72.1%, risk difference (RD) −0.01, 95% confidence interval (CI) 0.06–0.05) in the clinical evaluable populations. Overall 28-day mortality did not differ between novel β-lactam/β-lactamase combinations and the meropenem group (RD, −0.02, 95% CI, −0.09 to 0.05). Regarding the microbiological eradication rate, novel β-lactam/β-lactamase combinations were non-inferior to meropenem for Pseudomonas aeruginosa, Klebsiella pneumoniae, Proteus mirabilis, Haemophilus influenzae, Staphylococcus marcescens, and Enterobacter cloacae. Finally, novel β-lactam/β-lactamase combinations had a similar risk of (i) treatment-emergent adverse events (RD, 0.02, 95% CI, −0.02 to 0.06), (ii) events leading to the discontinuation of the study drug (RD, 0.00, 95% CI, −0.02 to 0.03), (iii) severe adverse events (RD, 0.03, 95% CI, −0.01 to 0.07), and (iv) death (RD, 0.02, 95% CI, −0.02 to 0.05) when compared with meropenem group. In conclusion, our findings suggest that novel β-lactam/β-lactamase combinations of ceftolozane−tazobactam and ceftazidime–avibactam can be recommended as one of the therapeutic options in the treatment of NP/VAP." @default.
• W2989133719 created "2019-11-22" @default.
• W2989133719 creator A5010111029 @default.
• W2989133719 creator A5022398404 @default.
• W2989133719 creator A5075725551 @default.
• W2989133719 date "2019-11-13" @default.
• W2989133719 modified "2023-10-18" @default.
• W2989133719 title "Novel β-Lactam/β-Lactamase Combination Versus Meropenem for Treating Nosocomial Pneumonia" @default.
• W2989133719 cites W1969500929 @default.
• W2989133719 cites W1970599332 @default.
• W2989133719 cites W2154126135 @default.
• W2989133719 cites W2294833633 @default.
• W2989133719 cites W2408072278 @default.
• W2989133719 cites W2602847039 @default.
• W2989133719 cites W2734402341 @default.
• W2989133719 cites W2773548512 @default.
• W2989133719 cites W2793201120 @default.
• W2989133719 cites W2800508719 @default.
• W2989133719 cites W2826611979 @default.
• W2989133719 cites W2975920332 @default.
• W2989133719 cites W4239236691 @default.
• W2989133719 cites W4250547697 @default.
• W2989133719 cites W4376595642 @default.
• W2989133719 doi "https://doi.org/10.3390/antibiotics8040219" @default.
• W2989133719 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6963743" @default.
• W2989133719 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31766123" @default.
• W2989133719 hasPublicationYear "2019" @default.
• W2989133719 type Work @default.
• W2989133719 sameAs 2989133719 @default.
• W2989133719 citedByCount "5" @default.
• W2989133719 countsByYear W29891337192020 @default.
• W2989133719 countsByYear W29891337192021 @default.
• W2989133719 countsByYear W29891337192022 @default.
• W2989133719 countsByYear W29891337192023 @default.
• W2989133719 crossrefType "journal-article" @default.
• W2989133719 hasAuthorship W2989133719A5010111029 @default.
• W2989133719 hasAuthorship W2989133719A5022398404 @default.
• W2989133719 hasAuthorship W2989133719A5075725551 @default.
• W2989133719 hasBestOaLocation W29891337191 @default.
• W2989133719 hasConcept C104317684 @default.
• W2989133719 hasConcept C126322002 @default.
• W2989133719 hasConcept C197934379 @default.
• W2989133719 hasConcept C2775933652 @default.
• W2989133719 hasConcept C2776933286 @default.
• W2989133719 hasConcept C2776968632 @default.
• W2989133719 hasConcept C2777058267 @default.
• W2989133719 hasConcept C2777402170 @default.
• W2989133719 hasConcept C2777406300 @default.
• W2989133719 hasConcept C2777637488 @default.
• W2989133719 hasConcept C2777914695 @default.
• W2989133719 hasConcept C2779375183 @default.
• W2989133719 hasConcept C501593827 @default.
• W2989133719 hasConcept C523546767 @default.
• W2989133719 hasConcept C54355233 @default.
• W2989133719 hasConcept C547475151 @default.
• W2989133719 hasConcept C55493867 @default.
• W2989133719 hasConcept C71924100 @default.
• W2989133719 hasConcept C86803240 @default.
• W2989133719 hasConcept C89423630 @default.
• W2989133719 hasConcept C94665300 @default.
• W2989133719 hasConceptScore W2989133719C104317684 @default.
• W2989133719 hasConceptScore W2989133719C126322002 @default.
• W2989133719 hasConceptScore W2989133719C197934379 @default.
• W2989133719 hasConceptScore W2989133719C2775933652 @default.
• W2989133719 hasConceptScore W2989133719C2776933286 @default.
• W2989133719 hasConceptScore W2989133719C2776968632 @default.
• W2989133719 hasConceptScore W2989133719C2777058267 @default.
• W2989133719 hasConceptScore W2989133719C2777402170 @default.
• W2989133719 hasConceptScore W2989133719C2777406300 @default.
• W2989133719 hasConceptScore W2989133719C2777637488 @default.
• W2989133719 hasConceptScore W2989133719C2777914695 @default.
• W2989133719 hasConceptScore W2989133719C2779375183 @default.
• W2989133719 hasConceptScore W2989133719C501593827 @default.
• W2989133719 hasConceptScore W2989133719C523546767 @default.
• W2989133719 hasConceptScore W2989133719C54355233 @default.
• W2989133719 hasConceptScore W2989133719C547475151 @default.
• W2989133719 hasConceptScore W2989133719C55493867 @default.
• W2989133719 hasConceptScore W2989133719C71924100 @default.
• W2989133719 hasConceptScore W2989133719C86803240 @default.
• W2989133719 hasConceptScore W2989133719C89423630 @default.
• W2989133719 hasConceptScore W2989133719C94665300 @default.
• W2989133719 hasIssue "4" @default.
• W2989133719 hasLocation W29891337191 @default.
• W2989133719 hasLocation W29891337192 @default.
• W2989133719 hasLocation W29891337193 @default.
• W2989133719 hasLocation W29891337194 @default.
• W2989133719 hasOpenAccess W2989133719 @default.
• W2989133719 hasPrimaryLocation W29891337191 @default.
• W2989133719 hasRelatedWork W2152553897 @default.
• W2989133719 hasRelatedWork W2163292670 @default.
• W2989133719 hasRelatedWork W2345934860 @default.
• W2989133719 hasRelatedWork W2754495213 @default.
• W2989133719 hasRelatedWork W2790249024 @default.
• W2989133719 hasRelatedWork W2797979636 @default.
• W2989133719 hasRelatedWork W2982223601 @default.
• W2989133719 hasRelatedWork W3118439655 @default.
• W2989133719 hasRelatedWork W3200372697 @default.
• W2989133719 hasRelatedWork W4200180108 @default.

• next